Disease-associated prion protein (PrP Sc ) can be distinguished from the cellular isoform (PrP C ) by conformation-dependent immunoassay (CDI). This technique exploits the presence of an epitope, accessible in PrP C , but only unmasked by denaturation in PrP Sc . In this study, we investigated PrP Sc in different brain regions in variant and sporadic Creutzfeldt-Jakob disease (CJD) by using CDI, and directly compared the results with those obtained using the more commonly employed protease digestion and Western blotting. In general, there was good agreement between the results, although there were certain discrepancies in relative abundance when the regional distribution in variant CJD cases was considered. The results largely confirmed the previously described targeting of different brain regions by variant and sporadic CJD. Additionally, the combination of protease digestion and CDI detection demonstrated, for the first time, the presence of PrP Sc in variant CJD brains that is susceptible to proteolysis under standard conditions.
PrP
Sc in different brain regions in variant and sporadic Creutzfeldt-Jakob disease (CJD) by using CDI, and directly compared the results with those obtained using the more commonly employed protease digestion and Western blotting. In general, there was good agreement between the results, although there were certain discrepancies in relative abundance when the regional distribution in variant CJD cases was considered. The results largely confirmed the previously described targeting of different brain regions by variant and sporadic CJD. Additionally, the combination of protease digestion and CDI detection demonstrated, for the first time, the presence of PrP Sc in variant CJD brains that is susceptible to proteolysis under standard conditions.
Prion diseases are characterized by the conversion of the host-encoded prion protein (PrP C ) into a disease-associated isoform (PrP Sc ), which is thought to be the main component of the infectious agent or prion (Bolton et al., 1982; Prusiner, 1982 Prusiner, , 1998 . The conversion of a-helical PrP C into b-sheet-rich PrP Sc accompanies change in biochemical properties, such as protease resistance and detergent solubility (Meyer et al., 1986; Caughey et al., 1991; Pan et al., 1993) . The proteolytic treatment of PrP Sc leaves an N-terminally truncated, proteinase K (PK)-resistant core fragment of PrP Sc (termed PrP res ) (Oesch et al., 1985) . In human prion diseases, the presence of PrP Sc in a sample of affected tissue (usually grey matter enriched cerebral cortex or cerebellum) has been most commonly demonstrated by detecting PrP res by Western blotting. Variant Creutzfeldt-Jakob disease (vCJD) can be distinguished from sporadic CJD (sCJD) based on the PrP res type as determined by the size of the N-terminally truncated non-glycosylated fragment and the proportion of three possible glycoforms (Collinge et al., 1996; Head et al., 2004) . Additionally, the type of PrP res in combination with genotype at PRNP codon 129 has been proposed as the basis of a molecular classification system accounting for the marked clinico-pathological variability of sCJD (Parchi et al., 1999 ).
An alternative approach that also distinguishes PrP
Sc from PrP C is conformation-dependent immunoassay (CDI), which is based on a conformational transition in the N terminus of PrP during the formation of PrP Sc (Peretz et al., 1997) . CDI was initially developed in the form of a direct ELISA using the mAb 3F4 that binds to aa 109-112 of human PrP (Safar et al., 1998) . The epitope of mAb 3F4 was found not to be accessible in native PrP Sc , in contrast to its accessibility in PrP C , and was shown to become exposed in PrP Sc after denaturation (Safar et al., 1998) . The introduction of sodium phosphotungstic acid (NaPTA) precipitation and incorporation of a capture antibody into CDI greatly increased its sensitivity in detecting PrP Sc (Safar et al., 2002 (Safar et al., , 2005 Bellon et al., 2003) . CDI has been used to show that a significant proportion of PrP Sc in the brains of scrapie-infected hamsters is actually susceptible to proteolytic degradation (Safar et al., 1998) . In a subsequent study, up to 90 % of the PrP Sc present in the brains of patients affected with sCJD was reported to be PK-sensitiveIP: 54.70.40.11
On: Sun, 06 Jan 2019 09:51:40 (Thackray et al., 2007) . Moreover, various prion strains propagated in hamsters were reported to be distinguishable based on the ratio of PK-resistant PrP Sc to PK-sensitive PrP Sc (Safar et al., 1998) . Thus far, the presence or absence of PK-sensitive PrP Sc has not been reported in vCJD nor has a direct comparison been made between these two different PrP detection methods using well characterized human prion diseased brain specimens.
Brain tissue was taken from three vCJD cases and six sCJD cases, all with the MM genotype at PRNP codon 129. Three of the six sCJD cases were of the MM1 subtype and the other three cases were of the MM2 subtype, according to the classification system of Parchi and Gambetti (Parchi et al., 1999; Gambetti et al., 2003) . In each case, multiple samples (three times~100 mg in each sample) were taken from the frontal cortex (FC), cerebellum (Cb) and posterior thalamus (Th), homogenized, split and analysed separately by the two different methods, thus allowing direct comparison of the results. FC materials taken from five non-CJD cases were used as controls and expected to contain PrP C in the absence of PrP Sc . These control cases were referred to the National CJD Surveillance Unit as suspected of having CJD, but received an alternative diagnosis. Among the five neurological control cases, three cases were of the MM genotype at codon 129 of PRNP (with diagnoses of vascular dementia, motor neurone disease and B-cell lymphoma), one MV (with a diagnosis of vascular dementia) and one VV (with a diagnosis of dementia with Lewy bodies). The use of such neurological controls minimizes the possibility of inadvertently studying forms of PrP associated with pathological specimens in general or associated with neurological changes other than those associated with prion disease. Ethical approval for the use of brain materials was covered by LREC 2000/4/157 (Professor J.W. Ironside, University of Edinburgh, Edinburgh, UK).
The CDI method used in this study was performed as described previously (Bellon et al., 2003; Safar et al., 2005) , but omitting the NaPTA precipitation step. The explicit objective was to perform a discriminant test for PrP
Sc on the population of PrP molecules present in CJD and non-CJD brain as a whole, rather than on a subpopulation, as defined by their precipitation characteristics with this particular polyoxometalate. Briefly, a 5 % (w/v) brain homogenate prepared in PBS containing 2 % Sarkosyl was divided into two aliquots; one was mixed with the same volume of 8 M GdnHCl and denatured (D) and the other was diluted without GdnHCl and designated native (N). In certain experiments, samples were assayed by CDI after digestion with 2.5 or 50 mg PK ml 21 for 1 h at 37 u C. Both N and D samples were adjusted to a final concentration of GdnHCl of 0.35 M prior to CDI analysis using the capture antibody MAR-1 and europium-labelled detector antibody 3F4. MAR-1 recognizes a discontinuous epitope on human PrP that appears to involve an intact disulphide bridge between cysteine residues in helices two and three (Bellon et al., 2003) . The specific properties of mAb 3F4 on which PrP Sc -specific detection depend have been described above. The [D-N] values were obtained by subtracting timeresolved fluorescence (TRF) counts measured in the native state from those measured in the denatured state (Safar et al., 2005) . For the Western blot analysis of PrP res , the same 5 % brain homogenates as used for CDI analysis above were digested with 50 mg PK ml 21 for 1 h at 37 u C and analysed by Western blotting using the mAb 3F4 as described previously (Yull et al., 2006 (Yull et al., , 2009 .
When the FC samples from the neurological controls were examined by CDI, a slight increase in fluorescence signal was observed after denaturation. This was taken to represent experimental background in neurological control (non-CJD) tissue and the mean of these values was used to establish the cut-off used throughout this study. As expected, CJD samples had higher [D-N] values than those of controls, but were found to be variable between disease phenotypes and between brain regions. In vCJD, the [D-N] values for FC were lower than those of Cb and Th (Fig. 1a) . In contrast to vCJD, [D-N] values in both subtypes of sCJD were higher in the FC than the two other regions, except for case MM1-3, in which the values from FC and Cb were similar (Fig. 1b, c) . In two cases of the MM1 subtype of sCJD, the [D-N] values were highly variable between Th samples (MM1-2 and MM1-3). All three MM2 cases were similar and characterized by low [D-N] values, which were above background only in the FC tissues (Fig. 1c) . The difficulty in detecting PrP Sc in MM2 sCJD was unexpected; however, the results from analysis of an additional three MM2 sCJD cases (three samples from each of the three regions) were similar to those from the initial group of samples (data not shown), confirming that low levels of CDI-detectable PrP Sc characterize MM2 cases.
Western blot analysis confirmed the expected PrP res types in each homogenate (type 1 or type 2A in sCJD and type 2B in vCJD). In vCJD, the proteolytic fragments of PrP Sc (PrP res ) were readily detectable at short exposure times (30 s). In vCJD, PrP res signals from Th samples exceeded those of the corresponding FC or Cb (Fig. 2a) , whereas the mean CDI [D-N] values from Cb samples were higher than Th samples (Fig. 1a) (Fig. 1b) . In the MM2 subtype of sCJD, PrP res was reliably detectable only in the FC (Fig.  2c ) even after maximal exposure to the film of around 30 min.
Next, we turned our attention to the possible presence of protease-sensitive PrP Sc in these specimens. In order to compare the CDI signals before and after proteolysis, FC homogenates prepared from three CJD brains (vCJD3, MM1-3 and MM2-2) were allowed to remain undigested or digested with 2.5 mg PK ml 21 (mild proteolysis) or 50 mg PK ml 21 (standard proteolysis) and then analysed by CDI. Digestion with 2.5 mg PK ml 21 and CDI analysis in the native state abolished the signal seen in the absence of PK treatment (Fig. 3a) . This is taken to represent the loss of PrP C by mild proteolysis. However, the CDI signals from each CJD brain were readily detectable following denaturation of samples digested with 2.5 mg PK ml 21 (Fig.  3a) , indicating the presence of PrP Sc that resists mild proteolysis. After digestion with 50 mg PK ml 21 , a reduction of fluorescence signal was observed when compared with the results of the samples digested with only 2.5 mg PK ml 21 (Fig. 3a) . This loss of signal therefore corresponds to digestion of poorly protease-resistant forms of abnormal prion protein (or protease-sensitive PrP Sc ). Typically, around 60 % of the [D-N] values obtained following mild proteolysis was lost after digestion at the CJD brains with the MM genotype at codon 129. The brain homogenates used for CDI analysis in Fig. 1 were digested with PK at 50 mg ml "1 for 1 h at 37 6C and then analysed by Western blot by using mAb 3F4. Three cases each from vCJD (a), sCJD MM1 (b) and sCJD MM2 (c) were examined. In each row, the results from nine samples from each case (three samples per region multiplied by three regions) are shown. Molecular mass expressed in kDa is shown to the left. FC, Frontal cortex; Cb, cerebellum; Th, thalamus. higher (standard 50 mg ml 21 ) PK concentration (Fig. 3b) , indicating the presence of protease-sensitive in addition to protease-resistant PrP Sc in these human brain specimens. In a few vCJD samples, however, between 70 and 80 % of [D-N] value remained detectable after the standard proteolysis (Fig. 3b) , indicating that the protease-resistant PrP Sc predominated in these samples.
In this study, we have investigated the abnormal prion protein (or PrP Sc ) present in three different brain areas of three different CJD phenotypes using two different biochemical methods that are based on distinct molecular properties. When PrP Sc , as defined by the accessibility of 3F4-binding site (in CDI) was compared with that defined by resistance to limited proteolysis (in Western blot), the results were found to be similar, despite differences in the principle and platform. However, certain differences between the two measurements of PrP Sc was also seen; in all three vCJD cases, PrP res (based on PK-resistance) was more abundant in Th despite similar or higher levels of PrP Sc (based on CDI) being detected in Cb. The regional distribution of abnormal PrP in the three brain regions was different between vCJD and the two MM subtypes of sCJD. The PrP Sc burden in the vCJD brains appeared to be greater overall than in sCJD brains and differently localized: vCJD was characterized by PrP Sc in Cb and Th, whereas both types of MM sCJD had more abundant abnormal PrP in the FC consistent with previous studies of PrP res in sCJD cases (Parchi et al., 1996; Schoch et al., 2006) . It is interesting to note that a recent transmission study has shown that incubation periods with inocula prepared from vCJD Cb were consistently shorter than inocula from FC, suggesting higher titres of infectivity in the Cb (Ritchie et al., 2009) . All three cases of MM2 subtype of sCJD were characterized by relatively low level of PrP Sc as judged by CDI, consistent with CDI analysis of the National Institute of Biological Standards and Control CJD reference standards (Bellon et al., 2003) .
CDI analysis following proteolysis showed that PKsensitive forms of PrP Sc are present at readily detectable levels in CJD brains, but the levels are not always identical in samples of the same brain or even samples of the same brain region. Such micro-heterogeneity is also a feature of PrP res detection by Western blot and of PrP Sc detection by CDI in the absence of PK treatment. Nevertheless, the occasional discordance between CDI and Western blot might be explicable in terms of non-uniform distribution of PK-sensitive isoforms of PrP Sc in individual brain regions, although it is also possible that tissue-specific inhibition of PK activity may be partly responsible (Notari et al., 2008) . We note that our estimates of the proportion of PK-susceptible PrP Sc to total PrP Sc are not as high as those reported previously for sCJD (Safar et al., 2005) . The capture and detection antibody pairing of MAR-1 and 3F4 is common to both this study and that of Safar et al. (2005) and to our knowledge is the only antibody combination currently reported to result in human PrP Sc detection using CDI. An NaPTA precipitated fraction was used for CDI analysis in Safar's original study (Safar et al., 2005) , whereas a cleared brain homogenate representing the full spectrum of the PrP isoforms present was analysed directly, without prior fractionation in our study. It is not clear whether this methodological difference could account for our lower estimate of PK-susceptible PrP Sc , because NaPTA precipitable PrP from CJD brain has been previously reported to be largely PK-resistant in Western blot analysis (Wadsworth et al., 2001; Gambetti et al., 2008) . An alternative explanation is that the discrepancy between Safar's study and ours relates to case-to-case and sample-to-sample regional variation in the relative contribution of protease-resistant and protease-sensitive isoforms.
The biological significance of PK-sensitive PrP Sc is currently unclear. It remains to be determined whether it is a metabolic intermediate in the formation of PK-resistant PrP Sc or whether it represents another pathogenic isoform of PrP, but one which is not associated with the metabolic pathway leading to the formation of PK-resistant PrP Sc (Tzaban et al., 2002; Tremblay et al., 2004) . Serial transmission of PK-sensitive synthetic prions, which were generated by polymerizing recombinant mouse PrP into amyloid fibres, did not lead to the formation of PK-resistant PrP (Colby et al., 2010) , suggesting that PK-sensitive PrP Sc may be biologically relevant to disease pathogenesis. Whether and how it might contribute to the biological properties of prions such as infectivity and strain characteristics (Cronier et al. 2008; Deleault et al., 2008) remain to be shown, but the possible presence of PK-sensitive PrP Sc should be borne in mind in situations where a discrepancy between levels of infectivity and PrP res become apparent.
